Oral Semaglutide: Adherence, Side Effects & Patient Choice Q&A
- Patients taking oral semaglutide are more likely to discontinue treatment compared to those using the injectable form, primarily due to the less rigid dosing schedule associated with the...
- Oral semaglutide offers a more flexible dosing schedule than its injectable counterpart, which requires weekly administration.
- As stated by industry experts, this lack of strict adherence is a key factor driving higher discontinuation rates with the oral formulation.
In this Q&A, Richard Frank, MD, MHSA, discusses key considerations when choosing between oral and injectable semaglutide (Wegovy; Novo nordisk), emphasizing that clinical efficacy, safety, and side effect profiles are largely similar between teh 2 formulations. He explains that differences in real-world adherence are driven less by tolerability and more by how the medications are taken, with the daily, highly structured requirements of the oral formulation posing potential barriers to long-term persistence compared with the once-weekly injectable option. Frank highlights the importance of shared decision-making, noting that patient preference, lifestyle, and expectations should guide therapy selection, and underscores the critical role pharmacists play in educating patients on proper administration, managing side effects, and setting realistic expectations for long-term, chronic weight management therapy.
Pharmacy times: How do the clinical outcomes of the newly approved oral semaglutide for weight management compare with injectable GLP-1 therapies in terms of weight loss efficacy and durability?
Richard Frank, MD, MHSA: Absolutely. So I think there were 2 major trials, one for the oral Wegovy and then the other for the injectable Wegovy. I’m using Wegovy simply as I don’t want to confuse it with Ozempic, which is designated for diabetes.
The OASIS 4 trial (NCT05564117) for oral Wegovy at the maximum dose of 25 milligrams daily led to approximately a mean weight reduction of about 13.6%,or rounded up to 14%. Roughly 79% of participants achieved 5% or more weight reduction. That’s an important cut point because it’s what the CDC and typically other professional organizations argue is a clinically notable weight reduction.
In the STEP trial (NCT03548935) for injectable Wegovy, which is a bit older-by a couple of years now-the maximum dose of 2.4 mg led to roughly a 14.9% weight reduction, so rounded up to 15%, with 86% of participants achieving 5% or more weight reduction.
Semaglutide Discontinuation Rates and Patient Adherence
Table of Contents
Patients taking oral semaglutide are more likely to discontinue treatment compared to those using the injectable form, primarily due to the less rigid dosing schedule associated with the oral medication. While both formulations exhibit relatively high discontinuation rates in the second year as patients reach their weight loss goals, the oral agent presents greater challenges to consistent adherence.
Oral Semaglutide Dosing Flexibility and Potential for Non-Adherence
Oral semaglutide offers a more flexible dosing schedule than its injectable counterpart, which requires weekly administration. This flexibility, while potentially convenient for some, can lead to inconsistent adherence. Patients may choose to take the oral agent at varying times – evening, night, or morning – or even the day before or after the prescribed time, reducing the rigor of treatment.
As stated by industry experts, this lack of strict adherence is a key factor driving higher discontinuation rates with the oral formulation.
Discontinuation Rates in the Second Year of Treatment
Both oral and injectable semaglutide experiance elevated discontinuation rates in the second year of treatment. This trend is largely attributed to patients achieving their desired weight loss and afterward seeking to discontinue the medication. Though, the oral formulation consistently demonstrates a higher overall discontinuation rate compared to the injectable.
While specific discontinuation rate percentages were not provided in the source material, the facts confirms a notable difference in adherence between the two methods of administration. Further data on specific discontinuation rates can be found in clinical trial results published by Novo Nordisk, the manufacturer of semaglutide.
Implications for Patient Management
Understanding the factors influencing discontinuation rates is crucial for healthcare providers managing patients on semaglutide. Addressing potential adherence challenges with oral semaglutide through patient education and support may help improve treatment outcomes.
The source material suggests that the convenience of oral administration doesn’t necessarily translate to better long-term adherence, highlighting the importance of individualized treatment plans and ongoing monitoring.